Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action

Imad El-Kebbi

Nayda Bidikian

Layal Hneiny

Mona Nasrallah

Follow this and additional works at: https://red.library.usd.edu/ul-fp

Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Public Health Commons

Recommended Citation

El-Kebbi, Imad; Bidikian, Nayda; Hneiny, Layal; and Nasrallah, Mona, "Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action" (2021). Faculty Publications. 36. https://red.library.usd.edu/ul-fp/36

This Article is brought to you for free and open access by the University Libraries at USD RED. It has been accepted for inclusion in Faculty Publications by an authorized administrator of USD RED. For more information, please contact dloftus@usd.edu.
Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action

Imad M El-Kebbi, Nayda H Bidikian, Layal Hneiny, Mona Philippe Nasrallah

ORCID number: Imad M El-Kebbi 0000-0003-4177-5438; Nayda H Bidikian 0000-0001-9717-8849; Layal Hneiny 0000-0003-1073-4879; Mona Philippe Nasrallah 0000-0001-7382-8835.

Author contributions: El-Kebbi IM conceptualized the outline, wrote major section of the manuscript, generated some of the tables and figures, and provided final review and edits of the manuscript; Bidikian NH contributed to the literature search, wrote a large portion of the manuscript, and generated some of the tables and graphs; Hneiny L performed the literature search, and wrote one small section of the manuscript; Nasrallah MP accepted the editor invitation, conceptualized the paper, wrote one section of the manuscript, generated one table, and proofread and edited the whole manuscript; all authors approved the final version of the manuscript.

Conflict of interest statement: All authors declare no relationships/conditions/circumstances that present a potential conflict of interest.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in

Abstract

Type 2 diabetes continues to be a serious and highly prevalent public health problem worldwide. In 2019, the highest prevalence of diabetes in the world at 12.2%, with its associated morbidity and mortality, was found in the Middle East and North Africa region. In addition to a genetic predisposition in its population, evidence suggests that obesity, physical inactivity, urbanization, and poor nutritional habits have contributed to the high prevalence of diabetes and prediabetes in the region. These risk factors have also led to an earlier onset of type 2 diabetes among children and adolescents, negatively affecting the productive years of the youth and their quality of life. Furthermore, efforts to control the rising prevalence of diabetes and its complications have been challenged and complicated by the political instability and armed conflict in some countries of the region and the recent coronavirus disease 2019. Broad strategies, coupled with targeted interventions at the regional, national, and community levels are needed to address and curb the spread of this public health crisis.

Key Words: Type 2 diabetes; Middle East and North Africa; Epidemiology; Prevalence; Prediabetes; Complications

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
El-Kebbi IM et al. Diabetes in the MENA region

INTRODUCTION

The worldwide prevalence of diabetes mellitus continues to grow with no sign of reversal. Data from the World Health Organization (WHO) shows that diabetes rose 80% in prevalence between 1980 and 2014[1], and the International Diabetes Federation (IDF) estimates that in 2019, 9.3% of the global adult population age 20-79 years suffered from diabetes[2]. Compared to high income countries (HIC), this increase disproportionately affects low- and middle-income countries and adds a burden of excess morbidity, mortality, and health care costs[3]. Specifically, the Middle East and North Africa region (MENA) carried the highest prevalence of diabetes in 2019 at 12.2% and is expected to witness a 96% increase in diabetes prevalence between 2019 and 2045, second only to the African region with a 143% projected rise[4]. To compare, over the same time period, the prevalence in Europe and North America/Caribbean regions is expected to increase by 15% and 33%, respectively. Moreover, 44.7% of people with type 2 diabetes (T2D) in the MENA region are unaware of their condition[4].

Despite the heterogeneity within the MENA countries in terms of culture, income, population size, and sociopolitical stability[5,6], multiple common predisposing factors for diabetes have been implicated, including aging of the population, the change in lifestyle with reduction in physical activity, and increased consumption of calories and unhealthy food items, which have led to a rise in the prevalence of overweightness and obesity[2]. Genetic and epigenetic factors may also be contributing elements[7]; in a region that has a high rate of consanguinity[8], multiple gene loci that predispose to diabetes have been identified in the Eastern Mediterranean Region (EMR) population[9]. In addition to diabetes, prediabetes has been identified in a sizable proportion of the MENA population[2], out of whom a majority is expected to progress to diabetes over time[10].

This unrelenting diabetes epidemic was an important driving factor that spurred the 2011 declaration of the United Nations general assembly, in which countries committed to work on national plans for preventing and controlling noncommunicable diseases (NCD)[11]. In addition to the risk factors behind the worldwide rise in diabetes prevalence, other factors, specific to the MENA region, are contributing to the epidemic[12]. Measures to address the high numbers in the MENA area have been ineffective partly due to inadequate funding, insufficient commitment, political instability, and armed conflict in multiple countries[13,14].

This review aims at describing the current prevalence of diabetes and prediabetes in the MENA region, the contributing risk factors, common diabetes complications, and strategies that can help curb its spread and complications.

METHODOLOGY

We searched Medline (OVID electronic database Ovid MEDLINE(R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily 1946 to December 07,
2020) for studies reporting in 20 countries of the MENA region not only diabetes mellitus and cardiovascular diseases (CVDs), but also diabetic foot or amputation, diabetic nephropathies, diabetic retinopathy (DR), the prevalence of diabetes, and the prevalence of diabetes for the pediatric and adolescent age group. Each of the latter searches was exported into Endnote X9 Software, and the library was screened for relevant literature. The search did include the Medical Subject headings (MESH) for all the concepts except for countries in which keywords were added along to MESH to ensure a wider range of results. Only articles in the English language and with studies where specific complication prevalence was evaluated were selected for our paper. We limited the prevalence studies to publications within the last decade (2010-2020). For diabetes prevalence studies, we excluded hospital and clinic-based studies.

There has been no consensus on which countries define the MENA region. For our review, we have included the following 20 countries: Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates (UAE), and Yemen. These countries are commonly included in the definition of EMR (EMRO). Therefore, we included data from the WHO, which reports on EMRO, and IDF, which reports on MENA.

PREVALENCE OF T2D

Diagnostic criteria for diabetes

The diagnostic criteria for diabetes by the American Diabetes Association (ADA) include the following: hemoglobin A1c 6.5%, fasting plasma glucose 126 mg/dL (7.0 mmol/L), oral glucose tolerance test with 2 h plasma glucose 200 mg/dL (11.1 mmol/L), or casual plasma glucose 200 mg/dL (11.1 mmol/L) in the presence of hyperglycemic symptoms[15]. It is worth noting that the IDF follows the ADA criteria in the diagnosis of T2D[16]. On the other hand, the WHO defines diabetes as raised fasting glucose 126 mg/dL (7.0 mmol/L), history of diabetes, or using antidiabetic medication[17]. Unless stated otherwise, the studies included in the prevalence paragraph follow either ADA or WHO diagnostic criteria.

Prevalence

In 2019 and as previously stated, 9.3% of adults were living with diabetes worldwide, with a predicted rise to 10.2% and 10.9% by years 2030 and 2045, respectively. The highest age adjusted prevalence was reported in the MENA reaching 12.2%, where 1 in 8 adults was living with diabetes[2]. The WHO provides periodic country-specific rates of diabetes compiled from various studies[17]. We used WHO data to rank MENA countries by diabetes prevalence between 2000 and 2014[17], as shown in Figure 1.

The highest age standardized diabetes prevalence in the MENA region in the year 2000 was in Kuwait with a prevalence of 15.4%, and the lowest prevalence was 6.8% in Yemen. Between 2000 and 2014, all 20 countries of the MENA region discussed in this paper experienced an increase in prevalence while Kuwait kept its first ranking among these countries, for having the highest prevalence among them at 19.6% (Figure 1). Kuwait has already exceeded its projected prevalence of diabetes for 2030, which was anticipated to be 16.9%[18]. Another high-income country, Qatar, ranked second in prevalence among MENA countries, following Kuwait, both in 2000 and 2014 (Figure 1). In Saudi Arabia, a cross-sectional study was conducted from 2007 to 2009 and included 18034 individuals older than 30 years. It found the prevalence of diabetes was 25.4% (out of which 10.2% were previously undiagnosed), and it was significantly higher in urban compared to rural areas[19].

Moving to Pakistan, in 2017, a large-scale national study including 18856 adults (above 20 years of age), found that T2D prevalence was 16.9% (n = 3201), and diabetes was significantly associated with age[20]. In 2019, the age-adjusted comparative prevalence in Pakistan rose to 19.9%, and that country was ranked first among the MENA countries for having the highest number of people (19.4 million) living with diabetes[2]. To understand the trend in diabetes prevalence in Jordan, four surveys using the same diagnostic criteria (the WHO criteria) were conducted in the years 1994, 2004, 2009, and 2017. Over the years, the age-adjusted prevalence increased from 17.1% in 2004 to 22.7% in 2017. This steep increase was attributed not only to increased incidence, but also to other factors like aging of the population and better survival of individuals with diabetes. In addition, the percentage of previously diagnosed diabetes increased as well, accounting for 82.6% of all diabetes cases in 2017, indicating
Figure 1 Middle East and North Africa countries ranked by prevalence of type 2 diabetes in 2000 and 2014 (prevalence and confidence intervals are in %)[1]. CI: Confidence interval.

improved screening and diabetes awareness[21].

Moving to North Africa, and according to the WHO, the prevalence of diabetes in Egypt in 2014 was 17.9%, the third highest prevalence in the MENA region. In 2019, Egypt occupied the second highest rank among MENA countries with respect to number of adults living with diabetes, with almost 9 million cases[2]. However, within Egypt, the prevalence was much lower in rural areas compared to the national average. As an example, a community-based cross-sectional study conducted in Qena Governorate over 2 years (2013-2015) found that 811 out of 9303 had T2D (8.7%). It is worth noting that the majority of participants (n = 7701) were younger than 40 years of age, which likely contributed to the relatively low prevalence in this governorate[22].

In a neighboring country to Egypt, Tunisia, the most recent national cross-sectional survey we could identify was conducted in 2005 and involved 7700 adults, age 35 to 70 years. It found that the prevalence of T2D, based on WHO criteria, was 15.5%. Again, within that study, the urban prevalence was twice as high as in rural areas (17.7% vs 9.7%, respectively)[23].

As for Iran, a national survey conducted in 2011 found that the prevalence of diabetes (T1D and T2D combined) was 11.4%, and the annual incidence was estimated to be 1%[24]. Two large community-based cross-sectional studies yielded the following: in the Yazd area of central Iran, out of 2269 adults above 20 years, the crude prevalence of self-reported diabetes in 2014-2015 was 14.1%, and 1 out of every 5 people over 40 years of age was living with diabetes[25]. In contrast, the Pars Cohort Study in Southern Iran conducted on 9264 adults aged 40-75 years, found a slightly lower prevalence of diabetes of 9.9% using self-report and fasting plasma glucose[26, 27]. In either case, the prevalence is increasing over time, as was shown in a 5 year study in the city of Ahvaz. Out of 593 participants above 20 years of age, the prevalence of diabetes was 15.2% in 2009 and increased to 20.9% in 2014[27]. In both Southern and Southwest areas of Iran, diabetes prevalence was positively correlated with low education level, body mass index (BMI), and age.

Moving to Lebanon, a cross-sectional national survey including adults above 25 years of age found a prevalence of self-reported diabetes of 8.3%; the prevalence was higher among older age, obese, and less physically active groups[28]. A more recent community-based survey that was conducted in Beirut in 2014, found that the prevalence of diabetes, based on self-report, fasting glucose, or hemoglobin A1c, was 18.0%. Similarly, increasing age and BMI were risk factors[29]. The higher prevalence reported in this study, compared to the previously mentioned one, can be attributed to the different diagnostic criteria of diabetes and the characteristics of the participants,
where they had a higher obesity rate and were residing in Beirut, the capital of Lebanon, unlike the first survey that included both an urban and a rural population. In 2019, the IDF estimated the age adjusted comparative diabetes prevalence in Lebanon at 11.2%[2]. Other countries in the MENA region did not have recent or large community-based studies to estimate the prevalence of diabetes in the population. These countries (except for Morocco and Algeria) are more likely to have political instability and/or conflict (Libya, Iraq, Yemen, Afghanistan, Syria, Palestine, and Bahrain). The most recent community-based survey from Syria was conducted in 2006 in the city of Aleppo and reported the total prevalence of T2D to be 15.6%, out of whom 5% were newly diagnosed, while the rest were self-reported cases. Like other studies, the prevalence was correlated with obesity and a positive family history[30]. In 2019, based on extrapolation from similar countries, the IDF stated that more than 1 million adults were living with diabetes in Syria[2]. Unfortunately, Palestine, like Syria, lacks recent surveys and studies on a national level; however, the IDF estimated that the prevalence of diabetes in Palestine was 7% in 2017[31] and 9.5% in 2019[2].

**Prevalence of diabetes by gender**
The prevalence of diabetes was higher in women than men in several of the MENA countries (Table 1). Yet, some countries showed a higher prevalence in males compared to females, as is the case for Lebanon[28]. Gender differences may vary even within regions of the same country; for example, women in Central Iran[25] and the rural area of Kurdistan province[32] had a higher prevalence than men, whereas no significant differences in prevalence by genders was observed in the Southwest of Iran [27].

Given that other global studies do not show a higher predisposition to diabetes among females, it is likely that it is the gender factor, and not the physiologic sex factor, that contributes to the risk. This is supported by the higher prevalence of obesity and sedentary lifestyle among women, as described in the risk factors section. The prevalence by gender is shown in Table 1 and Figure 2.

**Urban vs rural**
Studies mentioned previously for Egypt[21], Tunisia[22], and Lebanon[28,29] have shown a higher T2D prevalence in urban compared to rural areas. Similarly, a study including 9149 participants aged 7-80 years from Riyadh, the capital of Saudi Arabia, found that the prevalence of diabetes, based on the WHO definition, was 31.6%[33], which is higher than the overall reported national prevalence[17].

The higher urban compared to rural prevalence is not consistent across or within studies. For example, a national diabetes survey in Pakistan conducted in the years 2016-2017 found a significantly higher prevalence in urban vs rural areas among males above 60 years of age and among females; however, younger males showed a higher prevalence in rural areas[34].

Similarly, the prevalence of diabetes in Iran was higher in rural compared to urban areas; it was noted that in the rural population of Kurdistan province, the prevalence of T2D in 2011-2017 was 19.6%. The prevalence was significantly associated with age and lower level of education. In this specific population, genetic polymorphisms were more common among rural populations, predisposing them to a higher risk of diabetes[32].

It is likely that the difference in prevalence in urban vs rural areas is attributed to different nutritional habits, activity level, and possibly a more health-promoting environment.

**Unknown vs known diabetes**
The rate of unknown or undiagnosed diabetes can be detected by population-based studies that collect blood samples and measure hemoglobin A1c or glucose levels. The proportion of undiagnosed diabetes in the MENA region was 44.7% in 2019[16]. In Kuwait, a cross-sectional survey in 2007 found that 23 subjects out of 120 diabetic adults were previously undiagnosed (19%)[35]. Similarly, in Pakistan, the rate of unknown diabetes was 27%[34].

In central Iran, undiagnosed diabetes was found to be more common in men (4%) than in women (3.7%), and it was significantly associated with older age; the prevalence of undiagnosed diabetes was 4.8 times higher in the age group 60-69 years compared to the youngest age group 20-29 years, indicating a higher level of diabetes unawareness in the older population[25]. In Beirut (Lebanon), 26 subjects out of 90 were unaware that they had diabetes (29%)[29]. In Jordan, the percentage of newly diagnosed cases compared to all diabetic cases was 25.5% in 2004, and it dropped to 17.4% in 2017[21]. In Qena, Egypt, around 35% of all the diabetes cases (both types)
Table 1: Gender specific prevalence of type 2 diabetes in % (CI) in 20 Middle East and North Africa countries in 2000 and 2014 as reported by the World Health Organization[1] and for Palestine[144]

<table>
<thead>
<tr>
<th>Country</th>
<th>2000</th>
<th>2014</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>Men</td>
<td>Women</td>
</tr>
<tr>
<td>Afghanistan</td>
<td>8.1 (5.3-11.5)</td>
<td>8.5 (5.7-11.9)</td>
<td>11.6 (6.4-18.2)</td>
<td>12.2 (6.8-18.8)</td>
</tr>
<tr>
<td>Algeria</td>
<td>8.6 (6.0-11.8)</td>
<td>9.2 (6.5-12.3)</td>
<td>12.3 (7.4-18.8)</td>
<td>12.6 (7.7-18.9)</td>
</tr>
<tr>
<td>Bahrain</td>
<td>10.6 (7.6-14.2)</td>
<td>9.9 (7.1-13.5)</td>
<td>12.0 (7.0-18.5)</td>
<td>10.6 (6.1-16.7)</td>
</tr>
<tr>
<td>Egypt</td>
<td>10.8 (7.5-14.7)</td>
<td>13.3 (9.6-17.5)</td>
<td>16.0 (10.0-23.6)</td>
<td>19.8 (12.9-28.2)</td>
</tr>
<tr>
<td>Iran</td>
<td>7.4 (5.5-9.4)</td>
<td>8.5 (6.4-10.7)</td>
<td>11.4 (7.2-17.2)</td>
<td>12.9 (8.4-18.8)</td>
</tr>
<tr>
<td>Iraq</td>
<td>11.5 (8.2-15.4)</td>
<td>12.4 (9.1-16.2)</td>
<td>17.2 (10.7-25.3)</td>
<td>17.5 (11.1-25.4)</td>
</tr>
<tr>
<td>Jordan</td>
<td>12.0 (8.8-15.9)</td>
<td>14.0 (10.5-18.0)</td>
<td>16.5 (10.5-24.0)</td>
<td>17.2 (11.3-24.6)</td>
</tr>
<tr>
<td>Kuwait</td>
<td>15.3 (11.2-20.3)</td>
<td>15.6 (11.4-20.4)</td>
<td>19.7 (12.8-28.1)</td>
<td>19.6 (12.9-27.7)</td>
</tr>
<tr>
<td>Lebanon</td>
<td>9.0 (5.7-13.1)</td>
<td>8.4 (5.3-12.2)</td>
<td>14.5 (8.7-21.8)</td>
<td>12.2 (7.4-18.5)</td>
</tr>
<tr>
<td>Libya</td>
<td>10.7 (7.9-14.1)</td>
<td>12.2 (9.1-15.8)</td>
<td>15.2 (9.5-22.5)</td>
<td>16.6 (10.7-23.8)</td>
</tr>
<tr>
<td>Morocco</td>
<td>9.0 (6.2-12.4)</td>
<td>9.2 (6.4-12.6)</td>
<td>14.0 (8.4-21.5)</td>
<td>13.4 (8.1-20.5)</td>
</tr>
<tr>
<td>Oman</td>
<td>10.2 (7.6-13.6)</td>
<td>9.9 (7.3-13.1)</td>
<td>14.3 (8.6-21.7)</td>
<td>12.3 (7.4-18.4)</td>
</tr>
<tr>
<td>Pakistan</td>
<td>9.1 (6.3-12.2)</td>
<td>9.0 (6.3-12.2)</td>
<td>12.6 (7.0-19.5)</td>
<td>12.1 (7.0-18.6)</td>
</tr>
<tr>
<td>Palestine</td>
<td>10.6 (7.8-14.0)</td>
<td>11.8 (8.9-15.2)</td>
<td>16.5 (10.3-24.3)</td>
<td>17.5 (11.4-24.9)</td>
</tr>
<tr>
<td>Qatar</td>
<td>13.7 (9.9-18.1)</td>
<td>14.2 (10.4-18.5)</td>
<td>18.9 (12.0-27.0)</td>
<td>18.8 (12.2-26.8)</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>13.1 (9.8-17.1)</td>
<td>13.1 (9.8-17.0)</td>
<td>17.6 (11.5-25.4)</td>
<td>17.0 (11.1-24.4)</td>
</tr>
<tr>
<td>Syria</td>
<td>9.8 (7.0-13.2)</td>
<td>10.9 (8.1-14.2)</td>
<td>14.0 (8.5-21.0)</td>
<td>15.3 (9.6-22.4)</td>
</tr>
<tr>
<td>Tunisia</td>
<td>8.3 (6.0-11.1)</td>
<td>9.7 (7.2-12.7)</td>
<td>12.1 (7.4-18.3)</td>
<td>12.9 (7.9-19.0)</td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>11.8 (8.6-16.0)</td>
<td>12.4 (9.1-16.5)</td>
<td>15.0 (9.2-22.5)</td>
<td>15.4 (9.7-22.6)</td>
</tr>
<tr>
<td>Yemen</td>
<td>7.4 (4.5-11.3)</td>
<td>6.2 (3.6-9.4)</td>
<td>12.6 (6.7-20.6)</td>
<td>10.1 (5.3-17.0)</td>
</tr>
</tbody>
</table>

Figure 2: Prevalence of type 2 diabetes by gender in years 2000 and 2014 from the World Health Organization[1] and for Palestine[144].

were newly diagnosed[22], and Tunisia showed one of the highest rates of undiagnosed diabetes at 51.1%[23].
PREDIABETES

The development of diabetes tends to be a gradual process with rising glucose levels from the normoglycemic range to the diabetic range. This process is driven by a combination of metabolic disorders that include both insulin resistance and a progressive decline in insulin secretion[10]; the term prediabetes has been used to characterize the intermediate state between normoglycemia and the glucose levels that define diabetes[2,15]. Patients with prediabetes comprise those with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT)[15]. Like diabetes, patients with prediabetes are at an increased risk of cardiovascular events but to a lesser extent. Previous studies have suggested that up to 70% of patients with prediabetes will eventually progress to diabetes[10], however implementation of lifestyle changes or pharmacologic therapy may prevent or delay that progression[36]. It is estimated that 25%-50% of patients with prediabetes may progress to diabetes within 5 years of diagnosis[37].

In addition to the high prevalence of diabetes, countries in the MENA region also suffer from a high prevalence of prediabetes. The IDF estimates that in 2019, the worldwide age adjusted comparative prevalence of IGT in adults aged 20-79 years was 8.6%, with the European region being least affected at a prevalence of 4.4%, and the Western Pacific region having the highest prevalence at 10.4%[2]. The estimated MENA prevalence of IGT was intermediate at 9.2% and is projected to increase to 9.9% by 2045. Even though the projected prevalence goes up only by 0.7%, it translates into near doubling of the number from 35.5 million to 64.5 million adults with IGT mostly due to population growth.

Within the past 20 years, a relatively small number of studies have reported on the prevalence of prediabetes in the MENA countries, however there was a wide variability among them in the definition of prediabetes, the sample size and sampling technique, and the age group sampled (Table 2). Overall, there did not appear to be a major difference between gender subgroups. A relatively high prevalence of prediabetes was reported in Iraq[38], Saudi Arabia[19], the UAE[39], and Kuwait[40], ranging between 19.3% and 28.6%. An intermediate prevalence was found in the countries of Iran[41], Pakistan[34], and Qatar[42] with a prevalence ranging from 13.8% to 14.6%. The countries of Yemen[43], Syria[30], Oman[44], and Tunisia[45] boasted a relatively low prevalence with a range of 4.6%-9.0%. A Lebanese study limited to the greater Beirut area reported an unusually high prevalence of prediabetes of 40.3%[29]; the way prediabetes was defined could have been a factor affecting the results, since either an elevated fasting glucose or a high A1c were acceptable parameters, while most of the other studies limited the prediabetes definition to IFG.

The values estimated by IDF for the prevalence of IGT in 2019 are overall lower compared to those reported for individual countries in the table, possibly because IDF limited their data collection to studies of IGT and excluded those that had also included isolated IFG in the definition of prediabetes. In addition, for the IDF data, only Algeria, Jordan, Oman, Pakistan, Saudi Arabia, Palestine, and the UAE had estimates based on oral glucose tolerance test. Diabetes prevalence for the remaining countries were extrapolated using values from countries deemed to be similar (geographic location, World Bank income group, ethnicity, language, and IDF region) and may be under-estimated[4].

RISK FACTORS

Multiple risk factors have been implicated in the increase in T2D prevalence. The change to a more sedentary lifestyle and the westernization of dietary habits with a shift to fast food and items rich in refined sugar and animal fat play a major role. Additional factors may also contribute to the rising prevalence, including cigarette and waterpipe smoking[46], pollution of the environment[47], and a high prevalence of hepatitis C in some countries (mainly Egypt and Pakistan)[48,49]. Moreover, there is evidence that people in lower socioeconomic groups are at increased risk of T2D[50].

Genetics

In addition to the well-known contributing effect of aging, sedentary lifestyle, unhealthy diets, and obesity in the development of diabetes, genetics also appear to play a role. A family history of diabetes in first degree relatives has long been known to increase the diabetes risk by up to 3-fold[51].
Table 2: Prevalence of prediabetes (%) in some Middle East and North Africa countries

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Country, yr</th>
<th>Age group (n)</th>
<th>Definition of prediabetes</th>
<th>Sampling technique</th>
<th>Prevalence of prediabetes % (95%CI)</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasrallah et al.</td>
<td>Lebanon (Beirut area), 2014</td>
<td>≥ 18 yr (501)</td>
<td>IFG: FPG 5.6-6.9 mmol/L or A1c 5.8%–6.4%</td>
<td>Probability multistage random sampling</td>
<td>48.0 (40.6–55.4) 36.0 (30.7–41.3) 40.3 (36.0–44.6)</td>
<td>30.7</td>
<td>36.0</td>
<td>40.3</td>
</tr>
<tr>
<td>Mansour et al.</td>
<td>Saudi Arabia, 2007-2009</td>
<td>≥ 30 yr (18034)</td>
<td>IFG: FPG 5.6-6.9 mmol/L</td>
<td>Random household national sample</td>
<td>26.4</td>
<td>24.7</td>
<td>25.5</td>
<td></td>
</tr>
<tr>
<td>Al-Rubeaan et al.</td>
<td>United Arab Emirates (Al-Ain), 2005-2006</td>
<td>&gt; 18 yr (2455)</td>
<td>IFG: FPG 5.6-6.9 mmol/L or IGT</td>
<td>Simple random sample</td>
<td>19.7</td>
<td>22.8</td>
<td>22.8</td>
<td></td>
</tr>
<tr>
<td>Saadi et al.</td>
<td>Kuwait, 2014</td>
<td>18-69 yr (2561)</td>
<td>IFG: FPG 6.1-6.9 mmol/L</td>
<td>Random sample</td>
<td>19.3 (16.9–22.0) 19.5 (17.6–21.5) 19.4 (17.9–21.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esteghamati et al.</td>
<td>Iran, 2011</td>
<td>25-70 yr (11867)</td>
<td>IFG: FPG 5.6-6.9 mmol/L</td>
<td>Randomized multistage cluster sample</td>
<td>15.45 (12.71–18.18) 13.74 (11.55–15.94) 14.6 (12.41–16.78)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basit et al.</td>
<td>Pakistan, 2016-2017</td>
<td>≥ 20 yr (10834)</td>
<td>IFG: FPG 6.1-6.9 mmol/L or IGT</td>
<td>Multistage clustering technique</td>
<td>NA</td>
<td>NA</td>
<td>14.4</td>
<td></td>
</tr>
<tr>
<td>Bener et al.</td>
<td>Qatar, 2007-2008</td>
<td>&gt; 20 yr (1117)</td>
<td>IFG: FPG 5.6-6.9 mmol/L or IGT</td>
<td>Multistage stratified cluster sampling</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>13.8</td>
</tr>
<tr>
<td>Gunaid et al.</td>
<td>Yemen, 2000</td>
<td>≥ 35 yr (250)</td>
<td>IFG: FPG 5.6-6.9 mmol/L or IGT</td>
<td>Multistage random sampling</td>
<td>5.7 (2.8–8.6) 10.9 (7.1–14.7) 9.0 (6.0–12.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albache et al.</td>
<td>Egypt (Alexandria), 2006</td>
<td>≥ 25 yr (806)</td>
<td>IFG: FPG 6.1-6.9 mmol/L</td>
<td>Random sampling</td>
<td>10.4 (4.7–21.0) 6.8 (2.9–15.1) 8.6 (3.8–18.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Lawati et al.</td>
<td>Oman, 2000</td>
<td>≥ 20 yr (9838)</td>
<td>IFG: FPG 6.1-6.9 mmol/L</td>
<td>Multistage stratified probability sampling</td>
<td>7.1 (6.2–8.3) 5.1 (4.4–6.8) 6.1 (5.5–6.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IFG: Impaired fasting glucose according to specified glucose range; FPG: Fasting plasma glucose; IGT: Impaired glucose tolerance (using World Health Organization definition, glucose ≥ 7.8 but < 11.1 mmol/L; 2 h after 75 gm oral glucose load); CE: Confidence interval; NA: Not available; A1c: Hemoglobin A1c.

Reports from Palestine, Iran, and Lebanon showed that a positive family history of T2D raised the risk by 1.6, 1.8, and 3.4 times, respectively [28,52,53]. Moreover, despite a higher prevalence of obesity in North America and Europe, MENA has a comparatively higher prevalence of diabetes, suggesting the presence of a genetic predisposition to glucose intolerance. Genome wide association studies have yielded several single nucleotide polymorphisms that appear to be associated with the development of diabetes. A recent meta-analysis reported that, for people in the MENA area, 71 single nucleotide polymorphisms increased the risk of T2D by 24%-69% [7]. There was a strong association with single nucleotide polymorphisms in the TCF7L2 (in 9 countries) and CDKAL1 genes (in 4 countries), in addition to a variety of other loci, including ADIPOQ, FTO, MC4R. COL8A1, KCNQ1, ALX4, and HNF1A. TCF7L2 was the most widely reported gene in the region, in countries that include Palestine [34], Lebanon [35], UAE [56], Egypt [57], Qatar [58], and Tunisia [59]. In the Lebanese population, associations with T2D have been found with variants of the COL8A1, KCNQ1, ALX4, and HNF1A genes [60]. The high rate of consanguinity reported for the MENA region, varying from 30% and up to 60% [8], likely further enhances the genetic susceptibility observed.

Transition in nutrition

In addition to the genetic predisposition, a worldwide transition to unhealthy diets and reduction in physical activity [61] plays a role in the development of obesity and diabetes. Diets have shifted to a higher consumption of calories, processed food, and animal fat, and a lower intake of fiber, fruits, and vegetables. In particular, the MENA area has experienced a rapid rate of modernization and urbanization over the past decades. An analysis of food availability and consumption by Mehio Sibai et al [62]...
showed a gradual and significant rise in daily caloric, protein, and fat intake between 1969-1971 and 2002-2004. It is estimated that the energy supply during that period rose from 2200 up to 2930 kilocalorie per day. In parallel, there was an increase in sugar intake and a reduction in the intake of fruits and vegetables. In Saudi Arabia, a recent study of people aged 35-70 years showed that 34% of participants reported an unhealthy diet, with a higher rate in younger individuals and those living in urban areas[63]. Similarly, a review paper from Lebanon found a rising trend of increased energy consumption from fat and animal product in the population, with a reduction in carbohydrate and cereal intake[64]. Another study from Lebanon found that consuming minimally processed food such as fruits, vegetables, legumes, breads, and cheeses was less likely to be associated with the metabolic syndrome (odds ratio = 0.18, 95%CI: 0.04-0.77) and hyperglycemia (odds ratio = 0.25, 95%CI: 0.07-0.98) compared to the consumption of highly processed food such as fast foods, snacks, meat, nuts, sweets, and liquor[65].

Physical inactivity
With the rapid worldwide modernization and advancement in technology, a reduction in the rate of physical activity has occurred. In the MENA region, all countries have demonstrated an increase in physical inactivity, with a higher prevalence among females compared to males. Figure 3 shows the prevalence of physical inactivity in MENA countries subdivided by gender. Insufficient physical activity was defined as the percentage of the population aged above 18 years who are not performing at least 150 min/wk of moderate-intensity physical activity or its equivalent[66]. There was a very high prevalence of insufficient physical activity in the high income Gulf countries with a prevalence ranging from 33%-67%, possibly because of a shift from manual labor/high physical activity jobs to occupations that are more sedentary in the services sector[67]. A study in Saudi Arabia found that more than 90% of surveyed individuals had an inadequate level of physical activity[68]. In contrast, that prevalence was under 30% for Jordan, Morocco, and Tunisia. Females were consistently less active compared to males, possibly due to prevailing local customs in conservative countries where women may not spend as much time outside the home or in public places and may not frequent exercise facilities.

Obesity
Because of the adoption of unhealthy dietary habits and food choices, and the significant reduction in physical activity, the prevalence of obesity has been steadily increasing worldwide including in the MENA region. It is well-known that obesity is a significant risk factor for diabetes, with many studies showing a correlation between BMI and the incidence of diabetes[69].

Data from the WHO risk surveillance program has shown a significant rise in the rate of obesity across all countries. The countries most affected are the high-income Gulf countries, in addition to Egypt, Libya, Lebanon, and Iraq with rates exceeding 30%. In contrast, Afghanistan, Pakistan, and Yemen boasted a relatively low prevalence, ranging from 5% to 17%. However, all countries suffered a rise in obesity prevalence between 2000 and 2016, ranging from 30%-100% (Figure 4). Interestingly, females were disproportionately more affected than males, with a prevalence that is comparatively 1.5-fold to 2.0-fold higher. Specifically, the prevalence of female obesity exceeded 40% in some Gulf countries (Saudi Arabia, Kuwait, Qatar, and UAE), in addition to Egypt and Jordan[70] (Figure 5).

COMPLICATIONS OF DIABETES

Mortality
NCDs account for around 70% of deaths worldwide[70]. In 2019, diabetes was the ninth leading cause of death with around 1.8 million directly attributed to hyperglycemia[71]. In addition, CVD, which is the leading cause of death and commonly a chronic complication of diabetes[72], claimed during the same year around 9 million lives[71]. Since 2019 and up until January 2021, the coronavirus disease 2019 (COVID-19) pandemic had already surpassed world diabetes mortality with over 2 million deaths; however, diabetes was again an important risk factor for mortality or the development of severe COVID-19 infection[73].

Regionally, the MENA region scores the worst in terms of hyperglycemia-related mortality with an age-standardized mortality rate per 100000 (ASM) of 139.6 in 2016, followed by Southeast Asia, which has an ASM of 115.3 and in contrast to Europe with
Focusing on the MENA region, there seems to be a pattern of lower ASM mortality from NCDs (diabetes, CVD, cancer, and chronic obstructive pulmonary disease) for some HIC of the Gulf and for the North African countries. Thus, in 2016, the ASMs for Oman, Qatar, Bahrain, and UAE were 404.6, 425.5, 430.1, and 460, respectively; similarly, for the North African countries of Algeria, Tunisia, and Morocco, they were 430.7, 460.6, and 483.9, respectively. In contrast, in low/middle low-income countries, ASM was 681.0 for Pakistan, 805.3 for Afghanistan, and 819.7 for Yemen, per 100000.

The ASM from NCDs for the MENA countries as well as the absolute number of deaths from diabetes or from CVD are presented Table 3. In addition to the apparently higher mortality in middle-income countries and low-income countries, the largest proportion of diabetes-related deaths occur among individuals under 60 years of age, with loss of productive years, adding to the socioeconomic burden of diabetes.

Even if not leading to premature death, diabetes causes significant morbidity with disability, lower productivity, and quality of life. The MENA region again has the highest rate of disability-adjusted life years caused by diabetes.

Macrovascular complications

Having diabetes essentially increases the risk of having a major adverse vascular event defined as nonfatal myocardial infarction, stroke, heart failure, and/or cardiovascular death by 2-3-fold after adjusting for age, sex, and smoking status. We could not find any large cohort studies nor national data on the above hard outcomes even from countries with a high prevalence of T2D who have a national diabetes registry...
Table 3 Mortality from high glucose and cardiovascular disease extracted from the World Health Organization country profile data site for 2016[75]

<table>
<thead>
<tr>
<th>2016</th>
<th>Total population (million)</th>
<th>Age-standardized mortality rate for NCD per 100000</th>
<th>Diabetes deaths (n)</th>
<th>Diabetes mortality per 10000</th>
<th>CVD deaths (n)</th>
<th>CVD mortality per 10000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan (LIC)</td>
<td>32527000</td>
<td>805.3</td>
<td>7056</td>
<td>2.17</td>
<td>51244</td>
<td>15.75</td>
</tr>
<tr>
<td>Algeria (MIC)</td>
<td>39667000</td>
<td>430.7</td>
<td>8390</td>
<td>2.12</td>
<td>69173</td>
<td>17.44</td>
</tr>
<tr>
<td>Bahrain (HIC)</td>
<td>1377000</td>
<td>430.1</td>
<td>404</td>
<td>2.93</td>
<td>775</td>
<td>5.63</td>
</tr>
<tr>
<td>Egypt (MIC)</td>
<td>91508000</td>
<td>711.8</td>
<td>17851</td>
<td>1.95</td>
<td>245904</td>
<td>26.87</td>
</tr>
<tr>
<td>Iran (MIC)</td>
<td>79109000</td>
<td>532.5</td>
<td>14842</td>
<td>1.88</td>
<td>160823</td>
<td>20.33</td>
</tr>
<tr>
<td>Iraq (MIC)</td>
<td>36423000</td>
<td>604.5</td>
<td>7279</td>
<td>2.00</td>
<td>51593</td>
<td>14.16</td>
</tr>
<tr>
<td>Jordan (MIC)</td>
<td>7595000</td>
<td>542.4</td>
<td>2347</td>
<td>3.09</td>
<td>17814</td>
<td>17.62</td>
</tr>
<tr>
<td>Kuwait (HIC)</td>
<td>3892000</td>
<td>541.4</td>
<td>326</td>
<td>0.84</td>
<td>4552</td>
<td>17.62</td>
</tr>
<tr>
<td>Lebanon (MIC)</td>
<td>5851000</td>
<td>516.4</td>
<td>1886</td>
<td>3.22</td>
<td>17814</td>
<td>30.45</td>
</tr>
<tr>
<td>Libya (MIC)</td>
<td>6278000</td>
<td>567.0</td>
<td>1292</td>
<td>2.06</td>
<td>11638</td>
<td>18.54</td>
</tr>
<tr>
<td>Morocco (MIC)</td>
<td>34378000</td>
<td>483.9</td>
<td>10645</td>
<td>3.10</td>
<td>69457</td>
<td>20.20</td>
</tr>
<tr>
<td>Oman (HIC)</td>
<td>4491000</td>
<td>404.6</td>
<td>903</td>
<td>2.01</td>
<td>4047</td>
<td>9.01</td>
</tr>
<tr>
<td>Pakistan (MIC)</td>
<td>189000000</td>
<td>681</td>
<td>44666</td>
<td>2.36</td>
<td>411569</td>
<td>21.78</td>
</tr>
<tr>
<td>Qatar (HIC)</td>
<td>2235000</td>
<td>425.5</td>
<td>359</td>
<td>1.60</td>
<td>1054</td>
<td>4.72</td>
</tr>
<tr>
<td>Saudi Arabia (HIC)</td>
<td>31540000</td>
<td>508.5</td>
<td>3737</td>
<td>1.18</td>
<td>42440</td>
<td>13.46</td>
</tr>
<tr>
<td>Syria (MIC)</td>
<td>18502000</td>
<td>594.7</td>
<td>1322</td>
<td>0.71</td>
<td>37885</td>
<td>20.48</td>
</tr>
<tr>
<td>Tunisia (MIC)</td>
<td>11254000</td>
<td>460.6</td>
<td>3523</td>
<td>3.13</td>
<td>31987</td>
<td>28.42</td>
</tr>
<tr>
<td>UAE (HIC)</td>
<td>9157000</td>
<td>460</td>
<td>707</td>
<td>0.77</td>
<td>5970</td>
<td>6.52</td>
</tr>
<tr>
<td>Yemen (MIC)</td>
<td>26832000</td>
<td>819.7</td>
<td>3854</td>
<td>1.44</td>
<td>56793</td>
<td>21.17</td>
</tr>
</tbody>
</table>

NCD: Noncommunicable diseases; CVD: Cardiovascular disease; LIC: Low income countries; MIC: Middle income countries; HIC: High income countries.

and/or have a relatively well-funded health care system[79]. The heterogeneity of the MENA population, the presence or absence of risk factors, and the inconsistent definition of outcomes makes comparisons between individual regions challenging. However, a recent study of 143567 adults with diabetes aged 35-70 years from 21 countries around the world, including 5 countries from the MENA (Saudi Arabia, UAE, Iran, Palestine, and Pakistan) and followed for 9 years found an absolute incidence of major CVD among people with diabetes of 8.3; 9.2; and 10.3 per 1000 person-years in HIC, middle-income countries, and low-income countries, respectively, as compared to 3.4; 4.9; and 5.3 per 1000 person-years in people without diabetes, respectively[76].

Specific to the MENA, the Tehran Lipid Study sampled 1198 adults aged ≥ 30 years with T2D and followed them for a median of 10 years. It reported a 23.4% and 14.3% cardiovascular and all-cause mortality, respectively. More than half of the mortality was due to cardiovascular events. Risk factors for death were male gender, smoking, and hypertension[80]. In a sample of 1308 adults with T2D recruited from primary care centers in Palestine, the prevalence of self-reported CVD was 12.2%[81]. The prevalence for CVD for Iran[4,80] and Palestine[82] is shown in Table 4.

On the other hand, risk factors for CVD, such as hypertension, dyslipidemia, smoking, physical inactivity, and obesity, are well documented through the implementation of the STEPS program by the WHO for most countries[17]. As an example, the prevalence of raised blood pressure (systolic blood pressure ≥ 140 and diastolic blood pressure ≥ 90 mmHg) was 26.3% for the EMR, which is the second highest in the world, with no gender predilection. It ranged from a low of 16.2% in Oman to as high as 25.0% in Pakistan. Similarly, the habit of smoking was high in this population, with a large gender difference, with 36.3% of men being active smokers (third highest in the world) vs 2.9% of women[17]. Of more concern is that a
Table 4 Select studies reporting on diabetic foot ulcer and macrovascular complications of diabetes for the Middle East and North Africa region

<table>
<thead>
<tr>
<th>Complication</th>
<th>Ref.</th>
<th>Country</th>
<th>Sample size (% male)</th>
<th>Setting</th>
<th>Duration of diabetes (yr)</th>
<th>Method of assessment</th>
<th>Prevalence %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic foot ulcer</td>
<td>Assaad-Khalil et al [88], 2015</td>
<td>Egypt (Alexandria)</td>
<td>2000 (50.0)</td>
<td>Diabetes Foot Clinic</td>
<td>11.7 ± 8.3</td>
<td>Physical exam</td>
<td>8.7</td>
</tr>
<tr>
<td></td>
<td>Al-Rubeaan et al [89], 2015</td>
<td>Saudi Arabia</td>
<td>62681 (52.4)</td>
<td>Saudi National Diabetes Registry</td>
<td>13.3 ± 8.1</td>
<td>Chart review</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>Yazdanpanah et al [92], 2018</td>
<td>Iran (Ahfaz)</td>
<td>605 (42.8)</td>
<td>Diabetes Clinic</td>
<td>9.2 ± 7.1</td>
<td>Physical exam</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>AlAyed et al [93], 2017</td>
<td>Jordan</td>
<td>1000 (48.2)</td>
<td>Diabetes Clinic</td>
<td>57.1% ≥ 5</td>
<td>Physical exam</td>
<td>5.3</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>Akram et al[90], 2011</td>
<td>Pakistan</td>
<td>830 (49.0)</td>
<td>Outpatient Clinic</td>
<td>8.1 ± 6.2 low ABI; 4 ± 6.4 normal ABI</td>
<td>ABI below 0.9</td>
<td>31.6</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Saeedi et al[4], 2020</td>
<td>Iran (Kurdistan)</td>
<td>400 (18.0)</td>
<td>Diabetes Clinic</td>
<td>14.6 ± 4.1</td>
<td>Angiography or physician</td>
<td>21.7 (5.75 CABG, 3.75 angioplasty)</td>
</tr>
<tr>
<td></td>
<td>Abu Al-Halaweheid et al[81], 2017</td>
<td>Palestine</td>
<td>1308 (35.9)</td>
<td>Primary Care Centers</td>
<td>7.1 ± 6.3</td>
<td>Questionnaire</td>
<td>12.2 (myocardial infarction)</td>
</tr>
<tr>
<td></td>
<td>Afsharian et al[80], 2016</td>
<td>Iran (Tehran)</td>
<td>1198 (42.1)</td>
<td>Community-based NA</td>
<td>23.4</td>
<td>Physician assessment</td>
<td>23.4</td>
</tr>
</tbody>
</table>

ABI: Ankle brachial index; NA: Not available; CABG: Coronary artery bypass grafting.

Figure 5 Prevalence (%) of obesity by country among male and female adults aged 18 years or older. Obesity defined as body mass index ≥ 30 kg/m² (age-standardized estimate) in 2000 and 2016[70].

Substantial proportion of youth (aged 13-15 years) smoke cigarettes, reaching 10% in Qatar and 35% in the West Bank (Palestine)[82]. Additionally, the habit of waterpipe smoking is highly prevalent among youth in predominantly Arabic-speaking countries of the MENA region, with waterpipe exceeding cigarette smoking[82]. The prevalence of hypercholesterolemia (total cholesterol level ≥ 5.2 mmol/L) was 36.8% in the EMR [70], which is comparable to the world prevalence. However, there is a higher predisposition to the atherogenic dyslipidemias in this region, with an elevated prevalence of low high-density lipoprotein-cholesterol and familial hypercholesterolemia[83,84].

Given that the prevalence of CVD risk factors in the MENA region is high, it would be desirable to develop a predictive model adapted to its population. One such CVD predictive tool used 1314 Omani adults to develop it and another 405 individuals for validating it; that population sample was followed prospectively for 6 years and confirmed a 9% incidence of CV events[85].
Diabetic foot ulcers

Diabetic foot ulcers (DFU) are a consequence of neuropathy and/or peripheral vascular disease. The lifetime risk for a person with diabetes to develop a DFU is 15%-25%, and the global prevalence is 3%-8% [86]. In a systematic review of DFU involving Arabic speaking countries, a total of 9 studies were reviewed, representing 16512 participants recruited from outpatient clinics. The prevalence of DFU was available for the following countries: Saudi Arabia (8.5%), Egypt (3.6%), Jordan (4.6%), Bahrain (5.9%), and Iraq (2.7%) [87]. A clinic-based study of 2000 adults with T2D in Alexandria (Egypt) found that 8.7% had DFU [88]. In a retrospective review of 62675 patients in Saudi Arabia, the prevalence of DFU was 2.05%, with an additional 1.06% suffering amputations [89].

Risk factors for DFU were a longer diabetes duration, male gender, higher BMI, the presence of an abnormal ankle-brachial index [90], and sensory neuropathy [88,91,92]. Prevalence of amputations varied from 1% to 2% [91,95]. Among 840 patients with diabetes in the Saudi National Diabetes Registry, the risk of mortality rose with DFU and increased further in the presence of lower extremity amputation, with a standardized mortality ratio of 4.39 and 7.21, respectively [94].

Microvascular complications

Most studies reporting on microvascular complications from the MENA region are either clinic or hospital based. However, some countries, like Saudi Arabia, possess a national diabetes registry, and others such as Iran have large cohorts followed longitudinally, like the Tehran Lipid Cohort. Among the three microvascular complications of diabetes namely nephropathy, neuropathy, and retinopathy, the latter is the most documented and studied.

Retinopathy

The overall global prevalence of DR is 34.6%, including 7.0% proliferative DR and 6.8% clinically significant macular edema [95]. It is the most common cause of blindness in adults worldwide including the MENA region. The overall prevalence of DR in the MENA countries ranges from 12.6% to 37.8%, with proliferative DR ranging from 2.3% to 10.6% [96-99].

In a nationwide study of 50464 Saudi adults with T2D from the Saudi National Diabetes Registry, the prevalence of DR was 19.7%, with 10.6% proliferative and 5.7% clinically significant macular edema [100]. In a hospital-based study of 1325 adults with T2D from Egypt, the prevalence of DR was 20.5% [101]. In a clinic-based survey of 1308 Palestinian adults with T2D, the prevalence of DR using nonmydriatic images was 21.8% [81]. In a cross-sectional Tunisian clinic-based study of 2320 adults, the prevalence of DR was 26.3%, out of whom 3.4% had proliferative DR and 4.2% had clinically significant macular edema [102]. In a systematic review in Iran which included 17079 individuals, the overall prevalence of DR was 37.8%, with wide variability among regions [103]. The prevalence of DR for the various countries is shown in Table 5.

Importantly, retinopathy was found even among newly diagnosed adults with T2D. In Pakistan, DR was present at diagnosis in 15.9% of 958 adults with T2D [99]. Similarly, in Jordan, DR was documented in 7.9% of 127 adults with T2D within 6 mo of diagnosis [104]. Finally, in a retrospective chart review from Lebanon of 484 adults with T2D, DR was present in 26.6% at first ophthalmologic examination [105].

The elevated prevalence of DR at diagnosis is in line with the high proportion (44.7%) of undisagnosed diabetes for the MENA region [2]. It is likely that there is a latency period from onset of diabetes to time of its diagnosis, during which damage to the retina is taking place. In support of this theory is that duration of diabetes has been consistently reported as a risk factor for DR across most studies [96,100,101].

Elevated CRP levels are common in type 2 diabetes, and a meta-analysis of 37 studies showed that higher CRP levels were associated with a greater risk of developing diabetes [106]. This was replicated in a study of 1200 patients with diabetes, where higher CRP levels were associated with a greater risk of developing diabetes [107].

Nephropathy

Studies assessing nephropathy are more heterogeneous, with some reporting on albuminuria, others on glomerular filtration rate, and very few on end-stage renal disease. A global study evaluating the impact of diabetes on disability-adjusted life...
Table 5 Select studies reporting on microvascular complications of diabetes in the Middle East and North Africa region

<table>
<thead>
<tr>
<th>Complication</th>
<th>Ref.</th>
<th>Country</th>
<th>Sample size (% male)</th>
<th>Setting</th>
<th>Duration of diabetes (yr)</th>
<th>Method of assessment</th>
<th>Prevalence %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinopathy</td>
<td>Al-Rubeaan et al [89], 2015</td>
<td>Saudi Arabia</td>
<td>50464 (56.0)</td>
<td>Saudi National Diabetes Registry</td>
<td>13.4 ± 8.2</td>
<td>Chart review</td>
<td>19.7 (10.6 PDR)</td>
</tr>
<tr>
<td></td>
<td>Macky et al[101], 2011</td>
<td>Egypt</td>
<td>1325 (28.5)</td>
<td>Hospital-based</td>
<td>48% for 5-15</td>
<td>Slit lamp</td>
<td>20.5 (2.3 PDR)</td>
</tr>
<tr>
<td></td>
<td>Jammal et al [104], 2013</td>
<td>Jordan</td>
<td>127 (63.8)</td>
<td>Clinic-based</td>
<td>Newly diagnosed</td>
<td>Slit lamp</td>
<td>7.9</td>
</tr>
<tr>
<td></td>
<td>Uddin et al[99], 2018</td>
<td>Pakistan</td>
<td>958 (56.0)</td>
<td>Multi-Clinics</td>
<td>Newly diagnosed</td>
<td>Slit lamp</td>
<td>15.9</td>
</tr>
<tr>
<td></td>
<td>Abu Al-Halawe et al[81], 2017</td>
<td>Palestine</td>
<td>1308 (35.9)</td>
<td>Primary Care Centers</td>
<td>7.1 ± 6.3</td>
<td>Digital retinal photo</td>
<td>21.8</td>
</tr>
<tr>
<td></td>
<td>Elshafie et al[97], 2011</td>
<td>Qatar</td>
<td>540 (360/540)</td>
<td>Community-based</td>
<td>12.9 ± 9.1</td>
<td>Slit lamp</td>
<td>23.5</td>
</tr>
<tr>
<td></td>
<td>Heydari et al [106], 2012</td>
<td>Iran</td>
<td>1022 (40.2)</td>
<td>Clinic-based</td>
<td>11.2 ± 8.2 DR; 5.8 ± 5.4 no DR</td>
<td>Slit lamp</td>
<td>23.6</td>
</tr>
<tr>
<td></td>
<td>Arej et al[96], 2019</td>
<td>Lebanon</td>
<td>2205</td>
<td>Community-based</td>
<td>9.1 ± 7.1</td>
<td>Digital retinal photo</td>
<td>12.6</td>
</tr>
<tr>
<td></td>
<td>Kahloun et al [102], 2014</td>
<td>Tunis</td>
<td>2320 (39.8)</td>
<td>Hospital-based</td>
<td>7.6</td>
<td>Slit lamp</td>
<td>26.3 (3.4 PDR)</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>Al-Rubeaan et al [107], 2018</td>
<td>Saudi Arabia</td>
<td>54670 (51.2)</td>
<td>Saudi National Diabetes Registry</td>
<td>13.6 ± 8.1</td>
<td>ACR and GFR</td>
<td>10.8 (1.2 micro; 8.1 macro; 1.5 ESRD)</td>
</tr>
<tr>
<td></td>
<td>Uddin et al[99], 2018</td>
<td>Pakistan</td>
<td>958 (56.0)</td>
<td>Multi-Clinics</td>
<td>Newly diagnosed</td>
<td>ACR</td>
<td>24.0</td>
</tr>
<tr>
<td></td>
<td>Zakkerkish et al [110], 2013</td>
<td>Iran</td>
<td>350 (32.0)</td>
<td>Diabetes Clinic</td>
<td>4.6 ± 5.5</td>
<td>ACR</td>
<td>20.6 (5.1 macro)</td>
</tr>
<tr>
<td></td>
<td>Shahwan et al [108], 2019</td>
<td>Palestine (Ramallah)</td>
<td>550 (54.7); Age above 35 yr</td>
<td>Diabetes Clinic</td>
<td>8.9 ± 6.8</td>
<td>ACR</td>
<td>34.6 (5.8 macro)</td>
</tr>
<tr>
<td></td>
<td>Ali and Al Lami [109], 2016</td>
<td>Iraq</td>
<td>224 (58.9)</td>
<td>Diabetes Clinic</td>
<td>23.2% ≥ 9</td>
<td>ACR (2 out of 3)</td>
<td>16.1</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>Khedr et al[22], 2016</td>
<td>Egypt (Qena)</td>
<td>9303 (51.1); 837 with diabetes</td>
<td>Community</td>
<td>NR</td>
<td>MNSI, then ENG</td>
<td>18.5</td>
</tr>
<tr>
<td></td>
<td>Ghandour et al [114], 2018</td>
<td>Palestine (Ramallah)</td>
<td>517 (32.0)</td>
<td>Primary Health Clinic</td>
<td>9.0 ± 7.5</td>
<td>Monofilament test</td>
<td>38.2</td>
</tr>
<tr>
<td></td>
<td>Chahbi et al [115], 2018</td>
<td>Morocco</td>
<td>300 (50.7)</td>
<td>Diabetes Clinic</td>
<td>10.6 ± 7.4</td>
<td>Diabetic Neuropathy Score</td>
<td>15.4 (DN4 painful)</td>
</tr>
<tr>
<td></td>
<td>Garoushi et al [112], 2019</td>
<td>Libya</td>
<td>450 (50.2)</td>
<td>Diabetes Clinic</td>
<td>15.1 ± 7.1</td>
<td>Diabetic Neuropathy Score</td>
<td>42.2 (≤LANSS ≥ 12 pain)</td>
</tr>
<tr>
<td></td>
<td>Kiani et al[113], 2013</td>
<td>Iran</td>
<td>521 (NR)</td>
<td>Diabetes Clinic</td>
<td>9.2 ± 7.4</td>
<td>NSS and NDS</td>
<td>49.3</td>
</tr>
</tbody>
</table>

NR: Not recorded; MNSI: Michigan neuropathy screening instrument; ENG: Electroneurogram; PDR: Proliferative diabetic retinopathy; ACR: Albumin to creatinine ratio; S-LANSS: Leeds assessment of neuropathic symptoms and signs; NSS: Neuropathy symptom score; NDS: Neuropathy disability score; DR: Diabetic retinopathy; GFR: Glomerular filtration rate; ESRD: End-stage renal disease.

years in the EMR reported more than doubling of diabetes-related chronic kidney disease between 1990 and 2005[77]. This doubling was not only due to the increased prevalence of diabetes or aging but also due to more obesity, salt intake, and uncontrolled blood pressure[77]. In a national study from Libya, the estimated prevalence of end-stage renal disease was 624 per million. The major cause was diabetes, followed by hypertension[106].

The prevalence of microalbuminuria ranged from 10.8% in Saudi Arabia[107] to 34.6% in Palestine[108], with Iraq[109], Iran[110], and Pakistan[99] at 16.1%, 20.6%, and 24.0%, respectively. Macroalbuminuria constitutes about 15% of the reported albuminuria. The prevalence of nephropathy from selected studies is shown in Table 5.
Risk factors for albuminuria were elevated blood pressure, high BMI, duration of disease, hyperglycemia, and the presence of diabetes complications[107,109,110].

Neuropathy
Diabetic peripheral neuropathy is the most common complication of diabetes; at least 50% of individuals with diabetes will develop it to some extent[111]. Neuropathy negatively affects quality of life and constitutes a major risk for DFUs. Despite its high prevalence, studies on neuropathy are heterogeneous in terms of the populations studied, the setting (clinic or community-based), and the testing procedure used (questionnaire, monofilament test, or electroneurogram). Similarly, the prevalence in the MENA region varies from 18.5% (Egypt)[22] to 42.2% (Libya)[112] and 49% (Iran)[113], using a standardized scoring system. Using a simple monofilament test, the prevalence was 38% in an outpatient clinic in Palestine[114]. Painful neuropathy is less common and was 15.4% in a cross-sectional study of 300 adults in Morocco[115].

Increasing age, duration of disease, high BMI, poor glycemic control, smoking, and low educational level were predisposing factors[112,113]. Peripheral neuropathy is overall more common in men, whereas painful neuropathy was more common in women[115].

DIABETES IN CHILDREN AND ADOLESCENTS
Whereas diabetes in children and adolescents used to be mostly limited to T1D, there has been, over the last two decades, an increasing proportion developing T2D globally[15]. Moreover, in some countries, such as Japan, T2D in children and adolescents has become more prevalent than T1D[2]. Because of the earlier onset of the disease, affected children are expected to have a higher prevalence of complications in adulthood compared to others with adult-onset T2D within the same age group[17]. Furthermore, T2D starting at an early age would adversely affect productivity at its peak, raise the healthcare costs, and increase morbidity and mortality[15].

We could not find recent data about the overall prevalence of T2D in children and adolescents in the MENA region; however, data from specific countries reflect an increasing incidence and prevalence of T2D in this age group. In Kuwait, for instance, the incidence rate of T2D between 2011 and 2013 among children and adolescents, aged ≤ 14 years, was 2.56 per 100,000 per year[116]. In Qatar, there were no registered cases of T2D among children and adolescents before 2008. Afterwards, the incidence of T2D increased from 1.16 per 100,000 in 2012 to 2.72 per 100,000 in 2016[117]. In Saudi Arabia, a nationwide survey conducted over years 2007-2009 found that 0.45% of the adolescents aged less than 18 years were known to have diabetes; out of which, 0.07% was T2D (n = 17). Moreover, the prevalence of newly diagnosed IFG and diabetes (both types) were 6.1% and 4.3%, respectively[118]. In Riyadh, T2D in the age group 7-17 years was found to be more common than T1D with a prevalence of 4.5%-33.

Moving to Iran, from 2001 to 2011, 1% of adolescents developed prediabetes and T2D each year[119]. The study found that males were 1.28 times more likely to develop prediabetes and T2D than females, which differs from an American study for diabetes in youth, the SEARCH study, that found the prevalence to be higher among females. This lower prevalence among Iranian females could be attributed to the ethnic differences and to how prediabetes was defined. This study included IFG only in its definition of prediabetes, which is, in contrast to IGT, a more common phenotype in males than females, thus contributing to the higher prediabetes prevalence among Iranian males[119]. As for Lebanon, a cross-sectional study was conducted in 2007 among students aged 11-18 years at three private schools in an urban area. It found that 10.5% of the students had IFG, and 3.5% had diabetes. Among overweight and obese individuals, the risk of developing prediabetes or diabetes was 4.93 and 2.85 times higher, respectively. The diagnostic criteria used did not differentiate between T1D and T2D; however, since the majority of those diagnosed with prediabetes and diabetes were overweight or obese, they were likely insulin resistant. Therefore, T2D is on the differential and should be confirmed for such a patient profile[120].

Modifiable risk factors
Obesity: One of the most important risk factors for T2D in adolescents is obesity. In the UAE, the prevalence of prediabetes and T2D among overweight and obese public school students, aged 11-17 years, were 5.4% and 0.87%, respectively[121]. Furthermore, 100% of all the children and adolescents with T2D in Qatar were either overweight or obese[117], and 23.35% of Saudi adolescents with diagnosed diabetes
were obese[118].

Obesity presents a challenging health problem in the MENA region, where the rates of obesity have been increasing rapidly among children and adolescents at a faster rate than adults[122]. According to the WHO, the crude prevalence of obesity among children and adolescents in the region ranged from 2.4% in Afghanistan to 22.8% in Kuwait in 2016[123].

In Lebanon, two cross-sectional studies were conducted in 1997 and 2009 using the WHO definition for obesity in children and adolescents as age and sex specific scores + 2. The prevalence of obesity in the age group 6-19 years increased from 7.3% in 1997 to 10.9% in 2009[124]. Moreover, obesity was more common in boys (10.1%) than in girls (4.2%) in private schools, whereas there was no gender difference in public schools (6.7% and 6.0% for boys and girls, respectively)[120]. In Pakistan, recent data from Hazara city showed that the prevalence of obesity among school students was 4.78%, and similarly to Lebanon the prevalence was higher in private compared to public schools[125].

**Physical inactivity:** The Global School-based Student Health Surveys found that physical inactivity, defined as less than 60 min activity per day on 5 or more days in the past 7 d, was very high among children and adolescents in MENA countries and was higher in girls compared to boys. The prevalence was 65.4% in Lebanon, 72.5% in the UAE, 80% in Iraq, and more than 80% in many MENA countries, reaching as high as 90.6% in Egypt. The high sedentary lifestyle rates can be partly due to lack of encouragement of physical activities from parents, teachers, and friends, while favoring spending more time on other tasks such as their education[126].

**Non modifiable risk factors**

**Family history:** Along with obesity and physical inactivity, the genetic predisposition and family history present significant risk factors for T2D in adolescents[127]. The risk of abnormal glycemic status among Emirati school students was 1.9 times higher among those who have first degree relatives with diabetes; moreover, it was found that more than half of Emirati students with prediabetes and all those with T2D had a positive family history of diabetes[121]; the same applies to Qatari adolescents with T2D[117].

Other non-modifiable risk factors are low birth weight, maternal diabetes during pregnancy, and the postmenarchal phase in females[126]. During puberty, there is a physiological 30% increase in insulin resistance that, in the presence of other risk factors, can precipitate T2D; thus, the onset of T2D in youth is earlier in girls than boys and manifests itself usually during the second decade of life.

In summary, the youth of the MENA region are particularly vulnerable to developing T2D because of a culmination of risk factors. Multilevel interventions are needed to be able to effectively reverse this wave.

The management of T2D in children and adolescents presents a real challenge due to the poor adherence to the management recommendations of this age group and the difficulty in reversing obesity[128]; moreover, many of the young T2D patients are asymptomatic. Thus, it is important to screen those at risk. The ADA guidelines recommend screening children starting age 10 years or earlier (in case of an earlier onset of puberty) for all obese or overweight children if they have one additional risk factor[128]. The management for T2D in children and adolescents should include reduction of 7%-10% of the excess weight, physical activity for at least 60 min/d, and a healthy balanced diet rich in nutrients. Moreover, optimal blood pressure control and annual screening for neuropathy and retinopathy are crucial to prevent and manage complications[128]. All of these should be accompanied by educating patients and their parents about self-management including self-monitoring of blood glucose. We could not identify any studies from the MENA on the management of T2D in this age group.

**CHALLENGES**

In brief, the MENA region has the highest prevalence of T2D, and the rates continue to rise steeply. Furthermore, it has one of the highest diabetes related disability-adjusted life years and mortality rates from NCDs. Modifiable risk factors for both diabetes and its complications are highly prevalent in this population and extend to the pediatric and adolescent age group.
To address and reverse this situation is a daunting yet unavoidable task. Emerging factors add to the challenge, such as the increasing pollution level and environmental degradation, the high level of geopolitical instability, and most recently the COVID-19 pandemic. The latter two have had a direct impact on diabetes care.

Refugees and displaced people
In 2021, the United Nations High Commissioner Report indicated that there are 17.4 million refugees, internally displaced or physically constrained people in the MENA region. These are predominantly from Syria, Iraq, Yemen, and Libya[129]. They constitute about 3% of the MENA population, and 18% of the global population of concern. During the year 2000, 24 million Yemeni people depended on assistance. In parallel, the rates of extreme poverty have doubled in the region, from 3.8% to 7.2% between 2015 and 2018, and are likely to rise further due to the financial strain of the COVID-19 pandemic[130]. Furthermore, in 2020 the MENA region was deemed the ‘least peaceful’ area in the world with its many armed conflicts and/or political instability[131].

The above factors negatively influence NCDs in general and diabetes in particular. They also weaken the public healthcare system. The optimal management of diabetes requires a patient-centered approach with continuity of care[132]. Instead, in an unstable setting, the care is typically fragmented and interrupted, and the health of refugees and of displaced civilians is very likely to suffer. Unfortunately, very few national studies address the health status of refugees, so the prevalence of diabetes complications may be underestimated.

One such study was conducted in Lebanon on both the Lebanese population and Syrian refugees, as part of the STEPwise approach[133]. Out of 1899 Lebanese and 2134 Syrian adults aged 18-69 years, 51.2% of Lebanese had three or more cardiovascular risk factors vs 59.8% of Syrians. A 2014 survey by the United Nations High Commissioner Report found that close to 15% of adult Syrian refugees had at least one chronic condition, with 16% of those having diabetes, half of whom reported difficulties accessing health services[13]. With social instability and lack of security in parts of other MENA countries, it is expected that similar conditions may be prevalent[14]. The situation is likely to be complicated by poverty, food insecurity, poor nutrition, and inability to access health care. A concerted effort by the international community and governmental health agencies is needed to assist vulnerable people and provide them with access to medical care.

COVID-19 and diabetes
The COVID-19 pandemic has stressed the healthcare system and highlighted the need for a stronger infrastructure. Resources of all countries, even those that are relatively affluent, have been strained. National health systems should invest in interventions that aim at improving diabetes care. This is of paramount importance, in view of the data that shows a worse prognosis and an increased risk of complications and mortality for patients with diabetes hospitalized with COVID-19 infections[134]. A recent report from Qatar suggested that patients with diabetes hospitalized with COVID-19 infection had more severe clinical manifestations of pneumonia and acute respiratory distress syndrome and longer duration of hospitalization, intensive care stay, and mechanical ventilation[135]. Another study from Saudi Arabia reported that during the COVID-19 lockdown, patients with diabetes had reduced compliance with their medications and with healthy lifestyle habits[136]. Moreover, it is likely that many patients with diabetes have had a disrupted outpatient follow-up care due to visit cancellations during the pandemic, a situation that may adversely impact their overall diabetes control.

CONCLUSION

Call for action
There is ample evidence that diabetes can be prevented or delayed and its complications significantly reduced[137]. A recent editorial emphasized that worldwide implementation of diabetes prevention measures is an urgent matter[138]. Our review of T2D in the MENA region provides an opportunity to identify gaps and potential remedies for diabetes-related public health problems.

More accurate and complete data collection is needed for individual countries because available data is frequently scarce, outdated, relies on historical estimates, or is extrapolated from other similar countries. Without reliable data, the magnitude of
the problem can be under/overestimated, and areas of need cannot be properly identified.

In addition, the socioeconomic disparities in the care of diabetes need to be addressed because a lower socioeconomic background frequently emerged as a risk factor for diabetes and for complications. Strategies need to be put in place to address this issue, with interventions that are evidence-based, cost effective, and designed to improve access to care.

Another worrisome finding is the gender difference manifesting as a higher prevalence of obesity and physical inactivity among women compared to men. It calls for an investigation of potential reasons and for implementation of remedial solutions, especially that gestational diabetes carries the risk of generational transmission of metabolic syndrome[139].

Furthermore, there is an urgent need to introduce programs that educate about healthy nutrition choices and promote healthy habits. Proper monitoring of implementation of planned interventions followed by evaluation of their impact is mandatory. Strategies to promote and encourage physical activity are needed, whether through urban planning with introduction of sidewalks and walking trails or through building exercise facilities that are accessible and affordable.

Policies are needed to label food items with their nutritional and caloric content. Educational programs need to be introduced at the school, community, and workplace levels, with emphasis on adapting them to the local cultures and norms. To be effective, educational programs need to be culturally sensitive and tailored to the functional health literacy of the local population[140]. The national media and advertising industry need to be involved in educating the public, in partnership with the national health system. Telehealth may play an important role in terms of raising awareness and providing better access to care[141], especially in view of the geopolitical instability and the COVID-19 pandemic.

In addition, there is a need to promote a public health awareness at the level of primary health care providers for screening and managing diabetes and associated metabolic comorbidities. There is evidence to suggest that quality of care is not optimal[142]. Educational activities need not only address risk factors for diabetes such as obesity and unhealthy lifestyles but also how to manage diabetes and its potential complications and how to implement preventive measures to avoid complications, such as regular eye and foot exams and kidney function tests.

The prevention and management of diabetes should be the perfect prototype of ‘health into all policies.’ In 2013, the WHO announced the Global Action Plan for the Prevention and Control of Non-Communicable Diseases 2013-2020 aimed at curbing the rise in obesity and diabetes. However, it is evident that not enough has been done so far to achieve this goal, and efforts have fallen short of the magnitude of the problem. Therefore, national strategies need to be put in place to address noncommunicable diseases in general and diabetes in particular, with an emphasis not only on planning but also on implementation. In 2021, the WHO is launching the WHO Global Diabetes Compact, which would enable countries (especially low and middle income) to prevent diabetes by addressing risk factors and help these countries develop their capabilities in identifying and treating people with diabetes[143]. Such programs are urgently needed in the MENA region.

ACKNOWLEDGEMENTS

The authors would like to thank Dr Amy Zenger for her kind and valuable assistance in English revisions.

REFERENCES


**MENA Project.** European policy brief. [cited 27 Jan 2021]. In: Istituto Affari Internazionali [Internet]. Available from: https://www.iai.it/sites/default/files/mena_pb_2.pdf


International Diabetes Federation. Insulin at 100. [cited 27 Jan 2021]. In: International Diabetes Federation [Internet]. Available from: https://idf.org/


Mirzaei M, Rahmanian M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from
El-Kebbi IM et al. Diabetes in the MENA region


56 Osman W, Tay GK, Alsafar H. Multiple genetic variations confer risks for obesity and type 2 diabetes mellitus in arab descendants from UAE. *Int J Obes (Lond)* 2018; 42: 1345-1353 [PMID: 29717269 DOI: 10.1038/s41366-018-0057-6]


67 Sheriff S, Sumpio BE. Economic development and diabetes prevalence in MENA countries: Egypt


Disease study (Saudi-DKD): clinical characteristics and biochemical parameters. Al-Rubeaan K


El-Kebbi IM et al. Diabetes in the MENA region

2018; 38: 46-56 [PMID: 29295969 DOI: 10.1144/0256-4947-2018.03.01.1010]


The World Bank. MENA: Global Action is Urgently Needed to Reverse Damaging Jumps in Extreme Poverty, [cited 26 Jan 2021]. In: The World Bank [Internet]. Available from:


